Kedrion Biopharma

RYPLAZIM

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Kedrion Biopharma

Ryplazim HCPCS:

J2998

HCPCS Code Descriptor:

Injection, plasminogen, human-tvmh, 1 mg

Category:

J Code

Ryplazim NDCs:

70573-0099-02, 70573-0099-01

Primary Type:

Hematology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Ryplazim CPT Codes:

Potential CPT administration codes for Ryplazim can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

70573-0099-01

About Ryplazim:

RYPLAZIM is a Hematology drug manufactured by Kedrion Biopharma and administered via the Intravenous route of administration. The J Code: J2998 is aligned to the drug RYPLAZIM.

ACCESS PRICING AND MORE BY REGISTERING

J2998 Added Date:

July 1, 2022

J2998 Effective Date:

July 1, 2022

J2998 Termination Date:

HCPCS Active

Ryplazim billing and coding information can be found through Kedrion Biopharma at the link below:
Ryplazim patient assistance information can be found through Kedrion Biopharma at the URL: https://www.ryplazim.com/support/
RYPLAZIM prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for RYPLAZIM. Please check back in a few weeks.